S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

$9.15
+1.45 (+18.83%)
(As of 03/1/2024 ET)
Today's Range
$7.65
$9.17
50-Day Range
$7.55
$9.51
52-Week Range
$3.80
$12.31
Volume
1.28 million shs
Average Volume
514,441 shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Cytek Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
1.6% Downside
$9.00 Price Target
Short Interest
Bearish
6.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Cytek Biosciences in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$217,100 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.10) to ($0.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.34 out of 5 stars

Medical Sector

908th out of 950 stocks

Analytical Instruments Industry

28th out of 28 stocks


CTKB stock logo

About Cytek Biosciences Stock (NASDAQ:CTKB)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Stock Price History

CTKB Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Cytek Biosciences Reports Full Year 2023 Earnings
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Piper Sandler Keeps Their Buy Rating on Cytek Biosciences (CTKB)
The Latest Analyst Ratings for Cytek Biosciences
See More Headlines
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2022
Today
3/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
688
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
-1.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$2.58 million
Pretax Margin
-7.57%

Debt

Sales & Book Value

Annual Sales
$193.39 million
Cash Flow
$0.07 per share
Book Value
$2.91 per share

Miscellaneous

Free Float
113,997,000
Market Cap
$1.24 billion
Optionable
Optionable
Beta
1.41
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Wenbin Jiang Ph.D. (Age 60)
    President, CEO & Chairman of the Board
    Comp: $964.21k
  • Dr. Ming Yan Ph.D. (Age 61)
    CTO & Director
    Comp: $616.26k
  • Ms. Valerie T. Barnett J.D. (Age 49)
    General Counsel & Corporate Secretary
    Comp: $535.98k
  • Mr. Patrik Sebastian Jeanmonod (Age 58)
    Chief Financial Officer
    Comp: $412.54k
  • Mr. Chris Williams (Age 55)
    Chief Operating Officer
  • Mr. Paul D. Goodson
    Head of Investor Relations
  • Dr. Allen B. Poirson Ph.D. (Age 64)
    Senior Vice President of Business & Corporate Development
  • Dr. Philippe Busque Ph.D.
    Senior Vice President of Global Sales & Services
  • Ms. Connie Wedel
    Chief People Officer
  • Mr. Melik Ulusu
    Senior Vice President of Operations & Integrated Supply Chain














CTKB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CTKB shares.
View CTKB analyst ratings
or view top-rated stocks.

What is Cytek Biosciences' stock price target for 2024?

5 Wall Street analysts have issued 12-month price objectives for Cytek Biosciences' stock. Their CTKB share price targets range from $7.00 to $10.00. On average, they predict the company's share price to reach $9.00 in the next year. This suggests that the stock has a possible downside of 1.6%.
View analysts price targets for CTKB
or view top-rated stocks among Wall Street analysts.

How have CTKB shares performed in 2024?

Cytek Biosciences' stock was trading at $9.12 at the start of the year. Since then, CTKB shares have increased by 0.3% and is now trading at $9.15.
View the best growth stocks for 2024 here
.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings data on Wednesday, August, 10th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.01. The business had revenue of $40.16 million for the quarter, compared to analyst estimates of $41.34 million. Cytek Biosciences had a negative net margin of 5.86% and a negative trailing twelve-month return on equity of 1.23%.

What ETF holds Cytek Biosciences' stock ?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.

What guidance has Cytek Biosciences issued on next quarter's earnings?

Cytek Biosciences updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $203.0 million-$213.0 million, compared to the consensus revenue estimate of $207.1 million.

When did Cytek Biosciences IPO?

(CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Cytek Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Brown Capital Management LLC (8.86%), Vanguard Group Inc. (8.77%), New York State Common Retirement Fund (2.17%), Northern Trust Corp (0.88%), Dimensional Fund Advisors LP (0.79%) and Charles Schwab Investment Management Inc. (0.65%). Insiders that own company stock include Jack Ball, Ming Yan, Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang.
View institutional ownership trends
.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTKB) was last updated on 3/3/2024 by MarketBeat.com Staff